SNY Jan 2024 38.000 put
| Previous close | 1.7700 |
| Open | 1.7700 |
| Bid | 0.2500 |
| Ask | 4.4000 |
| Strike | 38.00 |
| Expiry date | 2024-01-19 |
| Day's range | 1.7700 - 1.7700 |
| Contract range | N/A |
| Volume | |
| Open interest | 56 |
ZacksSanofi (SNY) Gains But Lags Market: What You Should Know
Sanofi (SNY) closed at $51.01 in the latest trading session, marking a +1.09% move from the prior day.
ZacksPharma Stock Roundup: FDA Okays PFE RSV Jab for Elderly, AZN Ends Brazikumab Studies
FDA approves Pfizer's (PFE) RSV vaccine for older adults and AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated metastatic castration-resistant prostate cancer
ZacksThe Zacks Analyst Blog Highlights Fomento Economico Mexicano, NextEra Energy, Sanofi, NVIDIA and Enbridge
Fomento Economico Mexicano, NextEra Energy, Sanofi, NVIDIA and Enbridge are included in this Analyst Blog.
GlobeNewswirePress Release: Sanofi launches 2023 global Employee Stock Purchase Plan
Sanofi launches 2023 global Employee Stock Purchase Plan Paris, June 1 2023. Sanofi launches Action 2023, its global employee shareholder plan, open to around 86,000 employees in 56 countries. The program builds on plans carried out since 2013 and demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve all employees, across all its territories, in the future development and results of the company. Paul HudsonChief Executive Officer of Sanofi "This plan represents our
ZacksTop Stock Reports for FEMSA, NextEra Energy & Sanofi
Today's Research Daily features new research reports on 16 major stocks, including Fomento Economico Mexicano, S.A.B. de C.V. (FMX), NextEra Energy, Inc. (NEE) and Sanofi (SNY).
ZacksSanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal
Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the primary endpoint.
Motley FoolWas This $3 Billion Deal a Wise Move for Sanofi?
The French drugmaker appears to have meaningfully improved its portfolio with the acquisition.
- GlobeNewswire
Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis
Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis Frexalimab met primary endpoint with 89% reduction in new gadolinium-enhancing T1 brain lesions achieved at Week 12 in the higher-dose treatment arm, compared with placeboSanofi plans to initiate pivotal trials in multiple sclerosis in early 2024 Paris, May 31 2023. New data, being presented in a late-breaking session at the 2023 Consortium of
ZacksRegeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study
A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.
- GlobeNewswire
Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors
Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors Approval of the financial statements for the fiscal year 2022Distribution of a cash dividend of €3.56 per share, with payment as of June 1st, 2023Board composition: Frédéric Oudéa becomes Independent Director and Chairman of the Board Paris, May 25, 2023. The Combined General Shareholders’ Meeting of Sanofi was held on May 25, 2023, under the chairmanship of Serge Weinberg. The General Meeting approved
Motley Fool2 Bear Market Defying Stocks to Buy in May
This group of companies includes Sanofi (NASDAQ: SNY) and Axsome Therapeutics (NASDAQ: AXSM). France-based Sanofi is a biotech giant with a diversified portfolio of medicines and vaccines, although it is perhaps best known for being one of the leaders in the insulin market. The company grabbed headlines in this space earlier this year when it decided to cut the price of its top-prescribed insulin product, Lantus, by 78% and limit out-of-pocket costs to $35.
- GlobeNewswire
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placeboDupixent is the first and only investigational biologic for COPD that has significantly improved lung function at 12 and 52 weeks, with numerical improvements seen as early as 2 w
PR NewswireSanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi
Sanofi (NASDAQ: SNY) is pleased with the United States Supreme Court's ruling in Amgen v. Sanofi et. al. The decision unanimously affirms the United States Federal Circuit Court's opinion that is favorable to Sanofi and Regeneron.
- GlobeNewswire
Sanofi: Information concerning the total number of voting rights and shares – April 2023
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,521,494,572 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi
- GlobeNewswire
Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting
Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting HARMONIE Phase 3b data reinforce nirsevimab’s consistent and high efficacy against infant hospitalizations due to RSVData presented at ESPID add to the body of evidence demonstrating nirsevimab’s protection against RSV-related lower respiratory tract disease (LRTD) and confirm its favorable safety profile in multi-country, real-world conditions Paris, May 12, 2023. New data from the HARMONIE P
ZacksDenali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus
Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.
ZacksRegeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline
Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.
- GlobeNewswire
Sanofi: COMBINED GENERAL MEETING OF MAY 25, 2023 - AVAILABILITY OF PREPARATORY DOCUMENTS
COMBINED GENERAL MEETING OF MAY 25, 2023 AVAILABILITY OF PREPARATORY DOCUMENTS The Company’s shareholders are invited to attend the Combined General Meeting to be held on Thursday May 25, 2023 at 2:30 p.m. (CET) at the Palais des Congrès – Grand Amphithéâtre – 2, place de la Porte Maillot – 75017 Paris. The notice of meeting (avis de réunion), including the agenda and the draft resolutions as well as the terms and conditions for participating and voting in the meeting, was published on the websi
ZacksSNY or LLY: Which Is the Better Value Stock Right Now?
SNY vs. LLY: Which Stock Is the Better Value Option?
ZacksIs a Beat on the Cards for Regeneron's (REGN) Q1 Earnings?
Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent.
Motley FoolSanofi (SNY) Q1 2023 Earnings Call Transcript
SNY earnings call for the period ending March 31, 2023.
ZacksEli Lilly (LLY) Q1 Earnings Miss, Sales Beat, '23 View Raised
Eli Lilly (LLY) reports mixed results for the first quarter of 2023, missing estimates for earnings while beating the same for revenues. Management raises the 2023 outlook.
- Zacks
Sanofi (SNY) Q1 Earnings Beat, Sales Miss, Dupixent Strong
Sanofi (SNY) beats first-quarter estimates for earnings but misses the same for sales. Higher sales of Dupixent and rare disease drugs drive Specialty Care GBU sales.
- Zacks
Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Sanofi (SNY) have performed compared to their sector so far this year.
- GlobeNewswire
Press Release: Sanofi completes acquisition of Provention Bio, Inc.
Sanofi completes acquisition of Provention Bio, Inc. Paris, April 27 2023. Sanofi announced today the completion of its acquisition of Provention Bio, Inc. (“Provention Bio”). The acquisition adds TZIELD (teplizumab-mzwv), an innovative, fully owned, first-in-class therapy in type 1 diabetes to Sanofi’s core asset portfolio in General Medicines and further drives its strategic shift toward products with a differentiated profile. Olivier CharmeilExecutive Vice President, General Medicines, Sanofi